In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Vision

Exploring Latin America In The COVID-19 Era

Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?   

Government Payers Market Access

China Turns COVID-19 Crisis Into A Global Health Care Opportunity

Another important step has been taken under the Healthy China initiative, with the implementation on June 1 of a basic law on access to health care. This provides additional tailwind for a health system that appeared to efficiently contain its coronavirus outbreak and is now making further structural improvements.

Market Intelligence Medical Device

The Bigger Picture And Global Innovation Hotspots

Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally. 

Clinical Trials Business Strategies

Regulatory Harmonization Makes Big Strides In Africa

Last month a drug for the prevention of uterine haemorrhage became the first product to be approved under a novel scheme designed to speed up access to medicines in low and middle-income countries, particularly those in sub-Saharan Africa. 

Middle East and Africa Coronavirus COVID-19

COVID-19 Global Perspective

Infographic: As the novel coronavirus continues to cause disruption and leave casualties across the globe, In Vivo has taken a look at the activities of the life sciences sector in response. Here is a breakdown of biopharma and medtech research actions against COVID-19. 

Coronavirus COVID-19 Clinical Trials

Four Digital Saviors Of Indian Pharma During COVID-19

From digital marketing to payment systems, electronic solutions are aiding Indian pharma to ensure business continuity during the lockdown. New guidelines are spurring the adoption of telemedicine. Digital tools are connecting companies to their distribution chains and health care professionals. While some changes are here to stay, others might not stick.

Telehealth India

China Makes Its Mark On R&D Pipeline And Novel Launches

The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.

Clinical Trials Approvals

The Tensions In Pursuing Drug Price Transparency In Belgium

In Belgium, there are increasing tensions between drug price transparency and getting the best deal for the Belgian government.

Europe Belgium

Getting The Organizational Structure And Capabilities Of The Global Market Access Function Right

Hindsight is 20/20. Michael McLellan shares his opinions and recommendations for getting market access right, based on hindsight from 30 years of working in big pharma in both country-level and global roles.

Business Strategies Market Access

UK, Sweden Test Differing Antibiotic Market Models

Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries. 

Commercial Health Technology Assessment
See All
UsernamePublicRestriction

Register